FDA clears IND application for CAR-T to treat metastatic colorectal cancer

FDA clears IND application for CAR-T to treat metastatic colorectal cancer

The FDA cleared an investigational new drug application for GCC19CART, a chimeric antigen receptor T-cell therapy designed to treat patients with relapsed or refractory metastatic colorectal cancer.GCC19CART (Innovative Cellular Therapeutics) is an autologous, gene-edited CAR T-cell therapy that targets the enzyme guanylate cyclase 2C (GCC) on the surface of cancer cells.The agent is manufactured using ICT’s proprietary CoupledCAR technology to improve CAR T-cell efficacy in solid tumors.The IND clearance will allow the company to start enrollment of a clinical trial that will evaluateRead More

Share on facebook
Share on twitter
Share on linkedin